NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.29 -0.09 (-0.11%) GOLD FUTURES
2,323.10 -1.10 (-0.05%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
50,242.20 -534.76 (-1.05%)
Ginkgo Bioworks Holdings, Inc. (DNA)
After hours:
| Previous close | 0.9881 |
| Open | 1.0000 |
| Bid | 0.9376 x 1100 |
| Ask | 0.9500 x 3100 |
| Day's range | 0.9300 - 1.0100 |
| 52-week range | 0.7400 - 2.5450 |
| Volume | |
| Avg. volume | 30,897,824 |
| Market cap | 2.057B |
| Beta (5Y monthly) | 1.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4600 |
| Earnings date | 01 Mar 2024 - 05 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.92 |
PR NewswireGreenLab Partners with Ginkgo Bioworks to Scale Up Production of Brazzein, a Novel Sweetener
GreenLab, an emerging next generation plant-biotechnology company producing complex proteins in corn, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Together, GreenLab and Ginkgo aim to enable production of brazzein, a sweet-tasting protein found in the fruit of the native West African Oubli plant, at commercial scale. The two companies have previously partnered on a project to develop an enzyme for
PR NewswireGinkgo Bioworks Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, in Baltimore, MD. Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics. These presentations demonstrate the power of Ginkgo's platform to drive innovation in the discovery and development of genetic medicines.
Simply Wall St.Recent uptick might appease Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) institutional owners after losing 25% over the past year
Key Insights Significantly high institutional ownership implies Ginkgo Bioworks Holdings' stock price is sensitive to...
